Grant: Operating Grant
McGill University
$317,187.00
A Novel Method for Pharmacosurveillance: Combining an Electronic Prescribing and Drug Management System and Administrative Database
EF 2008-09
Résumé
Medications are the most frequent causes of preventable adverse events including illness, and death. Drugs do not have complete information on safety and effectiveness at the time of market approval. Present-day adverse drug reaction monitoring systems rely on health professionals to report and miss more than 90% of adverse drug reactions. There is an urgent need to develop better methods of monitoring the safety and effectiveness of drugs after they enter the market. The use of health administrative and electronic prescribing and health record data are two new approaches that could be used to provide a more timely and accurate detection of adverse drug effects. The purpose of this study is to evaluate the accuracy of administrative data in detecting adverse drug events, and the improvement in the accuracy of detection with the addition of electronic prescribing data. We will assess these new methods of post-market surveillance in a cohort of 2,300 patients within the primary care practices of 104 physicians using electronic prescribing systems. Patients who are newly prescribed drugs for hypertension, depression and pain will be included, as these medications are commonly prescribed and implicated in adverse drug events. We will use patient interviews and chart review to collect information about adverse effects during a 6 month follow-up period. We will use electronic prescribing orders for drug discontinuation due to adverse effects, as well as diagnostic codes in administrative records of medical visits and hospitalizations to determine whether these two sources of information can accurately detect the adverse drug events. The results of this study will be used to evaluate whether these new sources of information-administrative and electronic prescribing data-could be immediately used to institute a more effective means of monitoring the safety and effectiveness of drugs in Canada.
Programme
Operating Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
171474
Name
Tamblyn Robyn M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Public, Community and Population Health - B
Projecttitle
A Novel Method for Pharmacosurveillance: Combining an Electronic Prescribing and Drug Management System and Administrative Database
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$317,187
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Adverse Drug Reactions; Electronic Prescribing & Drug Managment System; Ineffective Treatments; Off-Label Indications; Patient Safety; Pharmacosurveillance
Abstract
Medications are the most frequent causes of preventable adverse events including illness, and death. Drugs do not have complete information on safety and effectiveness at the time of market approval. Present-day adverse drug reaction monitoring systems rely on health professionals to report and miss more than 90% of adverse drug reactions. There is an urgent need to develop better methods of monitoring the safety and effectiveness of drugs after they enter the market. The use of health administrative and electronic prescribing and health record data are two new approaches that could be used to provide a more timely and accurate detection of adverse drug effects. The purpose of this study is to evaluate the accuracy of administrative data in detecting adverse drug events, and the improvement in the accuracy of detection with the addition of electronic prescribing data. We will assess these new methods of post-market surveillance in a cohort of 2,300 patients within the primary care practices of 104 physicians using electronic prescribing systems. Patients who are newly prescribed drugs for hypertension, depression and pain will be included, as these medications are commonly prescribed and implicated in adverse drug events. We will use patient interviews and chart review to collect information about adverse effects during a 6 month follow-up period. We will use electronic prescribing orders for drug discontinuation due to adverse effects, as well as diagnostic codes in administrative records of medical visits and hospitalizations to determine whether these two sources of information can accurately detect the adverse drug events. The results of this study will be used to evaluate whether these new sources of information-administrative and electronic prescribing data-could be immediately used to institute a more effective means of monitoring the safety and effectiveness of drugs in Canada.
Competitiondate
200809
Approvedterm2
3 yrs 6 mths
Pinamesdelim
Tamblyn, Robyn M
Approvedterm
3 ans 6 mois
Cihrcontribution2
~ $317,187~ $0~